Players & stakeholders.
Eight regulatory triggers that put a trial on the schedule · five player categories that build it · ten stakeholder roles whose interests and leverage shape every protocol decision.
Eight regulatory triggers.
Why a clinical trial gets startedA clinical trial is a regulatory event answering a regulatory need. The eight triggers below are the most-frequent reasons a sponsor begins enrolment in 2026. Each carries a different design grammar — phase, comparator, sample size, endpoint, durability of follow-up — and each routes through a distinguishable regulator pathway.
Phase I FIH.
First-in-human single ascending dose. Healthy volunteers (or oncology patients for cytotoxics). Establishes preliminary safety, MTD, PK/PD. The point at which non-clinical extrapolation meets human reality.
Pivotal Phase III.
Adequate-and-well-controlled efficacy + safety in target indication. Two independent positive trials historically; FDA Complete Response Letters frequently cite single-trial designs that fail at filing.
Post-marketing Phase IV.
Required by approval (PMR/PMC in US, post-authorisation safety/efficacy study in EU, J-PMS in Japan). Real-world populations not represented in registration trials. Pharmacovigilance backbone.
Biosimilar comparability.
Demonstrating biosimilarity to a reference product. Step-wise: analytical → PK/PD → clinical. PD endpoints usually preferred over efficacy endpoints to detect differences sensitively.
Pediatric extrapolation.
Pediatric study plan (PSP) under FDARA / EU Pediatric Investigation Plan (PIP). Bayesian extrapolation from adult data with confirmatory pediatric PK/safety. Subpart D special protections under 21 CFR 50.
RWE filings.
Real-World Evidence as primary or supplemental. FDA RWE Framework Dec 2018 + 21st Century Cures Act §3022. EMA RWE pilot since 2021. Common for label expansions, single-arm registrations with external control.
Gene-therapy long-term follow-up.
FDA Long Term Follow-Up (LTFU) Guidance Jan 2020 expects up to 15 years of post-treatment surveillance for integrating viral vectors. EMA Annex on advanced therapy medicinal products (ATMPs) parallel.
Decentralised pilots.
Sponsor-driven hybrid or fully-decentralised studies validating DCT operating models. FDA DCT Guidance Sep 2024 + EMA Recommendation Paper Dec 2022. Often run before pivotal-design DCT for the same programme.
Five player categories.
Who actually runs a trialBeneath every trial sit five categories of player. The named entities below are illustrative incumbents in 2026 — not endorsements; the field is dynamic and acquisitions reorder the roster yearly. The categories themselves are stable.
Sponsors · big pharma.
Top-15 by R&D spend. Multi-therapeutic-area portfolios, in-house full-stack regulatory and clinical operations, deep integration with global regulators. Outsource selectively to CROs; retain pivotal Phase III in-house for many programmes.
Sponsors · emerging biopharma.
VC-funded, often single-asset or platform-centric. Lean clinical operations; outsource heavily to CROs, FSPs, and consultants. Frequently drive innovation in modality (gene therapy, cell therapy, mRNA, peptides, ADCs) and design (basket, umbrella, platform trials).
Contract Research Organisations.
Full-service or functional. Deliver protocol design, study management, monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory. The execution layer most sponsors run on.
Sites & investigators.
Where protocol meets participant. Academic medical centres, dedicated investigative-site networks, community-hospital practices, decentralised constellations. The Principal Investigator carries personal regulatory accountability under 21 CFR 312.60-69 and equivalents.
Regulators & ethics.
The arbiters. National medicines authorities issue Clinical Trial Authorisations (or accept notifications); Institutional Review Boards / Independent Ethics Committees approve protocols at the site or country level. Their findings shape every operational pillar above.
Ten stakeholder roles.
Interest · leverage · what they wantEach row below is a role with a distinct interest in the trial and a distinct lever to pull. Stakeholder analysis is what separates a politically-aware sponsor from one that experiences inspectorate findings, site walkouts, or participant-advocate dissent as surprise.